Consumer and environmental safety decisions are based on exposure and hazard data, interpreted using risk assessment approaches. The adverse outcome pathway (AOP) conceptual framework has been presented as a logical sequence of events or processes within biological systems which can be used to understand adverse effects and refine current risk assessment practices in ecotoxicology. This framework can also be applied to human toxicology and is explored, based around investigating the molecular initiating events (MIEs) of compounds. The precise definition of the MIE has yet to reach general acceptance. In this work we present a unified MIE definition: 2 an MIE is the initial interaction between a molecule and a biomolecule or biosystem that can be causally linked to an outcome via a pathway. Case studies are presented and issues with current definitions are addressed. With the development of a unified MIE definition the field can look towards defining, classifying and characterizing more MIEs, and using knowledge of the chemistry of these processes to aid AOP research and toxicity risk assessment. We also present the role of MIE research in the development of in vitro and in silico toxicology and suggest how, by using a combination of biological and chemical approaches, MIEs can be identified and characterized despite a lack of detailed reports, even for some of the most studied molecules in toxicology.
INTRODUCTION
Toxicology risk assessment is vital to the safety of consumers, workers and the environment.
Demands to produce assessments for an increasing number of compounds with fewer resources while cutting down on the use of animal testing has lead the field to look to non-animal alternatives including in vitro and in silico approaches. A large amount of the chemical and biological cause for toxicity remains unexplored as in vivo studies that focus more on apical endpoints at the highest levels of biological organization have historically been the preferred method for safety evaluation. A combination of new approaches and methods in biology and chemistry will lead to greater understanding of the processes connecting chemical exposure and adverse outcome. The adverse outcome pathway (AOP) framework for risk assessment brings this knowledge together in an attempt to develop predictive methods for human and environmental toxicology. The AOP can be defined as a sequence of events from the exposure of an individual to a chemical through to an understanding of the adverse effect at the individual level (for human health) or population level (for ecotoxicology). 1 AOPs span multiple levels of biological organization, but always contain an initial molecular interaction between a compound and the organism that triggers subsequent effects at higher levels of biological organization. This interaction is the molecular initiating event (MIE).
Figure 1.
The chemistry of the MIE is important to understand when developing predictive methods for human and environmental toxicology. The chemistry of the molecule allows it to have specific MIEs. Because of this, links between chemical structure or chemical property and molecular initiating event will undoubtedly be stronger than links to toxicological endpoints, due to a smaller "jump" between chemical exposure and MIE. It is accepted that a single MIE could be the cause of multiple toxicological endpoints, or that a single endpoint may be the result of several MIEs. Several compounds with vastly different chemical properties could result in the same endpoint. Attempting to build structure activity relationships (SARs) and quantitative structure activity relationships (QSARs) around these molecules will be vastly simplified by examining groups of compounds based on understanding of their MIEs.
A large amount of work has been done to group chemicals in toxicology based on receptor binding, [3] [4] [5] [6] one particular type of MIE. If a receptor has a single mechanism of binding, and hence is associated with a single MIE, we can confidently predict that a (Q)SAR based on this training set will be highly successful. However if the receptor is associated with several MIEs the (Q)SAR will not be effective. By gaining knowledge of these MIEs we can work towards generating more useful sets of data.
By combining knowledge about the MIE a compound is likely to activate with receptor binding and dose response data, and an understanding of adverse outcomes downstream in the AOP, quantitative predictions for new compounds could be made.
The recent search for alternatives to animal based toxicity testing has been well documented.
7,8
The limitations of animal experiments have been discussed 9-12 and new methods are being investigated to replace, reduce and refine approaches. 13 The MIE/AOP framework looks for mechanistic understanding, rather than to directly replace existing assays. This understanding is based, as much as possible, on human relevant data rather than in vitro data generated on nonhuman cells or read across from animal data. In this way mechanistic insights will aid a combination of approaches that will be required to reduce reliance on animal methods. Read across methods in hazard classification and the development of modelling potential beyond structural similarity represent recent approaches to developing (Q)SARs. The acceptance and use of even simple SAR techniques such as read-across and expert systems should lead to a reduction in the number of compounds needing to be tested using animals. 33 In toxicology (Q)SARs are currently used for screening rather than to provide leads for mechanisms. 34 Our vision for such (Q)SARs to be anchored to an MIE (or a series of MIEs) will relate chemical properties to activity more directly than ever before ( Figure 2 ).
Figure 2.
Classification of compounds by mode of action (MOA) using in vitro methods is already possible. 35 Application of this technology to search by MIE would yield useful results to be fed into predictive methods and to identify AOPs. In vitro toxicology can gain from enhanced knowledge of MIEs as well, by aiding in the interpretation of results and enabling the targeting of testing.
Interest in the application of MOAs and AOPs in predictive toxicology have already begun to appear, including the use of mode of action for aquatic toxicity prediction 36 and the application of the skin sensitization AOP to a risk assessment. 37 MIEs add a new level of understanding to
MOAs and AOPs that is gaining attention as basis for work into QSAR development, 38 category formation and read-across, 39 and molecular modelling leading to mechanistic understanding. 40 
THE MIE
As the key anchor for the AOP, and a commonly used term, an understanding of what an MIE is and how it should be defined is required. As AOPs become more prevalent, so will MIEs, particularly with the development of AOP maps and open source systems. 41 Several definitions for the MIE have been suggested:
1) The initial point of chemical-biological interaction within the organism that starts the pathway 42 or AOP. 34 2) Direct interaction of a chemical with specific biomolecules. 43 3) The molecular level, chemical-induced perturbation of a biological system. Current MIE definitions vary greatly depending on the field from which they originate and, hence, the types of interactions they are intended to describe. Some definitions omit a link to a pathway or endpoint. Some push the approach towards adverse outcomes, cutting off the term from being used to describe therapeutic applications. Some do not distinguish between the first molecular interaction in a pathway and any subsequent interactions. By taking the best features of the current definitions and using our database of MIEs 44 drawn from existing literature we suggest a unified definition to encompass all fields that should be useful to everybody using the concept of an MIE, and should promote discussion on the future of the area.
Our unified definition is:
A information is very difficult, and partial information from different sources must be brought together when evaluating MIEs. Incompleteness in parts is to be expected as even the most well studied chemicals lack detailed reports of molecular interactions. However, insights can be gained without the entire picture. Here we report detailed investigations of acetaminophen, amiodarone, chlorpromazine, kojic acid, methotrexate and valproic acid ( Figure 3 ). These structures have been chosen because they have diverse structures and activities, and because substantial amounts of data are available for all of them.
Figure 3
Acetaminophen Acetaminophen (or paracetamol) is a widely used, mild analgesic. While safe at recommended doses, acute overdose of acetaminophen is well documented to cause potentially fatal liver failure. This risk is increased when combined with alcohol abuse.
Acetaminophen is metabolized in several ways, but the most potentially hazardous is the P450 oxidation by the enzyme CYP2E1 to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). [46] [47] [48] While NAPQI only accounts for a small amount of acetaminophen ingested it is the main source of toxicity. This metabolism occurs in the liver, and hence most toxicity is located here.
Glutathione, a scavenger of oxidizing species in the cell, binds to NAPQI covalently 46,48 -forming a non-hazardous metabolite that is excreted in urine. chemically reactive molecules containing oxygen such as superoxides, peroxides and oxygen radicals, causing oxidative stress. These outcomes can lead to a mitochondrial permeability transition (MPT) 50,53-56 and can result in fatal hepatic damage. [50] [51] [52] [57] [58] [59] [60] [61] This toxicity is a good example of why dose must be accounted for -as only when the glutathione defense is overcome does the dose becomes toxic.
The metabolism of acetaminophen to NAPQI is the initial mechanism behind acetaminophen hepatic toxicity, making it an appropriate MIE. The ability of acetaminophen to be oxidised in this way is responsible for its toxicity, making this an appropriate MIE from which (Q)SARs are developed. Our definition fits this as the initial interaction with the biomolecule CYP2E1 can be linked to liver failure via several AOPs. The interaction of NAPQI with glutathione, proteins, nucleic acids or other biomolecules can be thought of as the MIE for NAPQI. However, with it not being the initial interaction this would be classed as another molecular interaction further along the AOP for acetaminophen. If the activations of a compound lack detailed study or the AOP is drawn differently, the MIE may change. For the purposes of this research, and to discover what it is about the administered drug that causes the adverse outcome, the initial oxidation is considered the MIE for acetaminophen.
Liver toxicity and acetaminophen are also being explored in other AOP pilot activities.
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Figure 4.
Amiodarone Amiodarone is a class III antiarrhythmic agent used to treat atrial and ventricular arrhythmias by suppressing abnormal rhythms of the heart. Despite having several common side effects, amiodarone is used in cases where the arrhythmias are difficult to treat with other medication.
Amiodarone is well reported to cause a condition known as amiodarone-induced pulmonary toxicity (APT), a combination of factors affecting the lung leading to pulmonary fibrosis. [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] This condition can be thought of as a combination of several factors discussed below, including Amiodarone uncouples mitochondria due to its properties as a mild base (pK a = 6.6 91 ), and its ability to cross the inner mitochondrial membrane. Amiodarone is protonated at the tertiary amine and translocates the proton from the mitochondrial intermembrane space to the matrix, dissipating the proton gradient required for efficient ATP production. 55, 56, 82, [89] [90] [91] This MIE can be highlighted as the interaction between Amiodarone and the biosystem contained within mitochondria, as it does not interact with a biomolecule to have this effect.
Amiodarone acts as an antiarrhythmic by inhibition of the human ether-a-go-go-related gene (hERG) channels. 55, [97] [98] [99] [100] [101] [102] The key structure for binding is a basic nitrogen flexibly attached to an aromatic ring. 97 The inclusion of hERG inhibition as an MIE highlights the importance of retaining therapeutic interactions as MIEs. Understanding the interactions between drugs and their targets is valuable knowledge when searching for new drug compounds, and as such this
should not be excluded.
Figure 5.
Chlorpromazine
Chlorpromazine is a dopamine antagonist and antipsychotic, used to treat schizophrenia.
Chlorpromazine is known to exhibit a number of toxicities including inducing hepatotoxicity and cardiac toxicity.
Two metabolic pathways lead to toxic derivatives of chlorpromazine:
• Peroxidase catalysed formation of the sulfur cation radical form of chlorpromazine.
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• Ring hydroxylations by P450 processes at the 7 104-106 and 8 105 positions. This leads to further oxidations forming 7,8-dioxochlorpromazine. 105 These toxic metabolites are neutralised by sulfoxidation -sulfoxidised chlorpromazine derivatives are non-toxic. 106 Oxidative stress is brought on via the production of Reactive Oxygen Species (ROS) by the action of chlorpromazine metabolites.
7-hydroxychlorpromazine is able to covalently bind to glutathione, depleting stocks of the scavenger, causing oxidative stress, 104 much like NAPQI. 7-hydroxychlorpromazine is also able to bind to other proteins in the cell, causing oxidative damage. 104 The chlorpromazine sulfur cation radical is a reactive species in itself. Co-oxidation of ascorbate, NADH and glutathione by the chlorpromazine sulfur cation radical, leads to oxidative stress. 103 7,8-dihydroxychlorpromazine is able to generate ROS directly by reaction with molecular oxygen. 105 While all of these metabolites cause oxidative stress, the MIEs for these processes are the metabolic interactions leading to the formation of the metabolites.
Chlorpromazine acts as an anti-psychotic via two MIEs. Chlorpromazine inhibits L-type calcium channels, preventing membrane depolarization and catecholamine secretion. 107, 108 It also inhibits nicotinic receptors, another pathway for preventing catecholamine secretion 108 .
Dopamine, norepinephrine and adrenaline are notable catecholamines. Increased levels of dopamine and norepinephrine are among the factors responsible for causing schizophrenia.
Chlorpromazine is known to cause phospholipidosis by inhibiting phospholipases. 74 Amiodarone causes the same AOP via phospholipase inhibition, and the MIE in this case is also poorly understood. The identification of several drugs activating the same MIE gives potential for structural comparison to identify features that may be responsible for poorly understood biological processes.
Chlorpromazine is known to inhibit hERG channels, leading to drug induced QT syndrome; lengthening of the QT interval. 107, [109] [110] [111] This gives chlorpromazine proarrhythmic potential in the same vein as amiodarone, which also inhibits hERG channels. Unlike amiodarone, chlorpromazine is known to cause torsade du pointes, a potentially fatal arrhythmic condition. 107, [109] [110] [111] Structural similarities between chlorpromazine and amiodarone known to be involved (flexible basic nitrogen attached to an aromatic ring) give mechanistic promise for this inhibition to be a single MIE activated by both compounds. 
Kojic acid
Kojic acid is produced by several species of fungi, including Aspergillus oryzae, known as Koji in Japan. It is found in several Japanese consumables including sake and soy sauce, leading to high exposures in Japan. 112 It is best known as a mild skin-lightening agent, used in cosmetics, and as to preserve the color of foods.
Kojic acid is effective as a skin lightening agent via the inhibition of melanosis, the process by which the dark pigment melanin is formed. [112] [113] [114] [115] [116] [117] The inhibition of tyrosinase is the primary action of the drug, via three MIEs:
• Chelation of kojic acid to the copper active site in tyrosinase. 115, 118 • Reduction of quinones to diphenols by kojic acid. 114, 118 • Kojic acid limiting the uptake of oxygen required for melanin formation.
112,114
The type of inhibition that dominates changes across species, 113 although competitive inhibition dominates in humans. [115] [116] [117] NF-kB is a protein complex in the skin which up-regulates the production of keratinocytes and melanocytes, cells responsible for the production of melanin. It is normally activated by UV radiation. NF-kB activity is suppressed by Kojic acid, down-regulating the production of melanin producing cells, causing lightening of the skin. 119, 120 It is accepted that UV induced ROS activate NF-kB, and kojic acid neutralizes these species in the extracellular environment as the MIE. 121, 122 It also chelates to iron, preventing the ROS being catalyzed to more hazardous free radicals, such as the hydroxyl radical. 122, 123 This mirrors the action of chelation to copper in tyrosinase inhibition.
The ability to limit oxygen uptake, reduce quinones and diphenols, and neutralization of ROS as MIEs are more appropriately described as interactions with biosystems rather than biomolecules.
Figure 7.
Methotrexate
Methotrexate is an antimetabolite and anti-folate drug, used in the treatment of leukaemia. It is well known for its action on the folic acid cycle. It is structurally similar to folic acid, giving it anti-folate characteristics.
In the treatment of leukaemia with methotrexate, one of the most common and damaging sideeffects is oral mucositis, a painful inflammation and ulceration of the mouth.
Methotrexate is a folate analogue. Structural similarities between methotrexate and folic acid dominate enzyme inhibitions. Inhibition of enzymes, such as dihydrofolate reductase (DHFR), leads to reduction of de novo biosynthesis of the nucleoside thymidine. [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] Thymidine is required for DNA synthesis. This gives methotrexate its anticancer activity. Inhibition of these enzymes also leads to a reduction in purine synthesis which in turn impacts on T cell activation, as a treatment for rheumatoid arthritis. 132 The majority of these inhibitions are competitive, due to folate similarities. 139 Oral mucositis is thought to be caused by two MIEs. The generation of ROS associated with methotrexate treatment, and the activation of NF-kB by methotrexate.
Methotrexate is known to decrease the number of oxidative species scavengers in the body. 140, 141 Methotrexate is reported to inhibit nicotinamide diphosphate (NADP) dependent dehydrogenase, leading to a deficiency of glutathione as NADP is a substrate for glutathione production. 140 Methotrexate also inhibits polyamine producing enzymes, resulting in the depletion of polyamine ROS scavengers. 129 Oxidative stress leads to the damage of DNA, among other biomolecules, and cell apoptosis, which is credited to contribute to mucositis. 142 The activation of NF-kB leads to the release of several cytokines inducing the formation of ulcers and tissue damage in the mouth leading to mucositis. 142 Oral mucositis can lead to infection and bleeding and, from either of these, death. 142, 143 Infection is especially high risk in patients receiving leukemia treatment, due to a low white blood cell count.
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Methotrexate is also reported to precipitate in the renal tubules of the kidneys, blocking them, especially in acidic urine. This leads to nephrotoxicity and overexpression of methotrexate.
124,144-
146 This is another case of the compound interacting with a biosystem, rather than a biomolecule as the MIE. 
Valproic acid
Valproic acid is used as an anticonvulsant and mood-stabilizing drug. Valproic acid is also under investigation as a histone deacetylase inhibitor, a potential activity against HIV and cancers. Valproic acid exhibits reproductive and hepatic toxicity.
Valproic acid is teratogenic -it induces malformations to an embryo or fetus in the womb. This is primarily through the inhibition of class I histone deacetylases (HDACs).
147-157
The inhibition of HDACs is suspected to occur via two MIEs:
• Binding of valproic acid to the catalytic center of the HDAC. 151, 158 • Down regulation of HDACs by proteosomal degradation.
147,151
Valproic acid activates Wnt-dependent gene expression through HDAC inhibition leading to increased expression of β-catenin and Tcf/Lef, much like another HDAC inhibitor, trichostatin A. 149, 156, 157 The teratogenetic effects associated with valproic acid and trichostatin A are very similar.
Using derivative analysis, very specific structural requirements were discovered for valproic acid to exert its teratogenicity. An sp 3 hybridized carbon, attached to a free carboxylic acid, two alkyl chains and one hydrogen. 149, 156, [159] [160] [161] Valproic acid acts as an anticonvulsant by increasing the concentration of γ-aminobutyric acid (GABA), an inhibitory neurotransmitter.
This occurs through four MIEs:
• Increasing GABA production, through stimulation of glutamic acid decarboxylase. 149, 156, 162 • And decreasing GABA catabolism, through:
o inhibition of GABA transaminase. 149, 150, 156, 162 o inhibition of succinate semialdehyde dehydrogenase. 149, 150, 156, 162 o and inhibition of α-ketoglutarate dehydrogenase. 149 Little mechanistic detail is available, but it is made clear that HDAC inhibition is not involved in anticonvulsant activity. 149 Studies into structural derivatives have shown that valproic acid represents a compromise of chain length and branching, between strongly inducing GABA concentration increase and decreasing toxicity and drowsiness. Longer alkyl chain lengths, branching at the 3 carbon, and replacing the acid with amide all resulted in increased anticonvulsant activity but also greater hepatotoxicity. Shorter alkyl chain lengths and making the drug linear or on a carbon ring decreased the anticonvulsant activity. 160 Valproic acid causes hepatotoxicity through microvesicular steatosis, [163] [164] [165] and is also connected to Reye's syndrome. 165 All are related to fibrosis of liver cells. All are caused by the inhibition of the β-oxidation of fatty acids in the liver, which in turn is caused by three distinct MIEs:
• Depletion of coenzyme A (CoA), a coenzyme required for the oxidation of fatty acids. 165 • Depletion of the biomolecule carnitine, which is required for the transportation of fatty acids to mitochondria for breakdown. 165 • Direct enzyme inhibition of β-oxidation.
163-165
Depletion of CoA is thought to occur via the formation of a CoA -valproate thioester. 165 The depletion of carnitine is poorly understood mechanistically, however we can speculate it may also have the ability to form an ester with valproic acid. These ester formations would represent the MIEs.
Direct inhibition of β-oxidation includes the enzyme CPT-1, 165 which is also inhibited by amiodarone via hydrophobic contacts. The prominence of hydrophobicity in the valproic acid structure would fit into the same MIE.
Structural derivative studies show valproic acid analogues to be more hepatotoxic with longer alkyl chains, and more branched alkyl chains -linking it to a hydrophobic mechanism. 160 Structural derivative studies help to classify the MIEs for teratogenicity and hepatotoxicity for valproic acid, as the structural features required for each can be elucidated. The hydrophobic side chains are responsible for the inhibition of CPT-1 leading to hepatotoxicity, while the sp3 hybridized carbon attached to two alkyl groups, a hydrogen atom and a carboxylic acid is responsible for the inhibition of HDACs leading to teratogenicity. 
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